Immunoprecise Antibodies Ltd (IPA) — Cash Flow-to-Debt Ratio
Immunoprecise Antibodies Ltd (IPA) has a Cash Flow-to-Debt Ratio of -0.05x as of April 2025, meaning its operating cash flow of $-1.14 Million could theoretically repay 0% of its total liabilities ($20.82 Million) in one year. See financial flexibility index of Immunoprecise Antibodies Ltd to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Immunoprecise Antibodies Ltd Cash Flow-to-Debt Ratio (1997–2025)
Historical debt coverage capacity for Immunoprecise Antibodies Ltd across 29 annual periods. For the full cash flow conversion analysis, see Immunoprecise Antibodies Ltd (IPA) cash conversion ratio.
Annual Cash Flow-to-Debt Ratio for Immunoprecise Antibodies Ltd (1997–2025)
Year-by-year debt coverage analysis for Immunoprecise Antibodies Ltd. Check how high is Immunoprecise Antibodies Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.31x | $-6.41 Million | $20.82 Million | ▼ -89.1% |
| 2024 | -0.16x | $-4.25 Million | $26.07 Million | ▲ +83.6% |
| 2023 | -0.99x | $-19.83 Million | $20.01 Million | ▼ -81.9% |
| 2022 | -0.54x | $-9.92 Million | $18.21 Million | ▼ -811.2% |
| 2021 | -0.06x | $-600.00K | $10.04 Million | ▲ +47.7% |
| 2020 | -0.11x | $-1.39 Million | $12.18 Million | ▲ +63.4% |
| 2019 | -0.31x | $-3.21 Million | $10.28 Million | ▼ -8.4% |
| 2018 | -0.29x | $-3.42 Million | $11.87 Million | ▲ +66.6% |
| 2017 | -0.86x | $-721.65K | $836.91K | ▼ -243.3% |
| 2016 | 0.60x | $284.09K | $472.15K | ▲ +524.3% |
| 2015 | -0.14x | $-36.11K | $254.64K | ▲ +7.7% |
| 2014 | -0.15x | $-46.60K | $303.50K | ▼ -840.9% |
| 2013 | -0.02x | $-4.33K | $265.63K | ▲ +97.4% |
| 2012 | -0.62x | $-132.72K | $213.10K | ▲ +14.6% |
| 2011 | -0.73x | $-80.39K | $110.21K | ▲ +76.9% |
| 2010 | -3.15x | $-308.49K | $97.87K | ▼ -205.4% |
| 2009 | -1.03x | $-155.68K | $150.84K | ▲ +92.6% |
| 2008 | -13.97x | $-523.45K | $37.46K | ▼ -1844.4% |
| 2007 | -0.72x | $-297.31K | $413.69K | ▲ +9.9% |
| 2006 | -0.80x | $-110.59K | $138.62K | ▲ +54.2% |
| 2005 | -1.74x | $-82.20K | $47.18K | ▲ +51.3% |
| 2004 | -3.58x | $-178.69K | $49.92K | ▲ +37.2% |
| 2003 | -5.70x | $-168.38K | $29.53K | ▼ -281.9% |
| 2002 | -1.49x | $-280.23K | $187.72K | ▼ -16357.5% |
| 2001 | -0.01x | $-8.13K | $896.75K | ▲ +100.0% |
| 2000 | -20.63x | $-208.54K | $10.11K | ▼ -263.7% |
| 1999 | -5.67x | $-202.94K | $35.78K | ▼ -68.5% |
| 1998 | -3.37x | $-226.81K | $67.39K | ▼ -677.8% |
| 1997 | -0.43x | $-108.20K | $250.04K | — |